What is the therapeutic effect of levacetylleucine?

Levacetylleucine is a novel therapeutic drug that was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Niemann-Pick disease type C (NPC; rare disease), a rare genetic lysosomal disorder. NPC patients often face systemic, neurological and psychiatric symptoms, which seriously affect the patient's quality of life and daily functions. To date, existing treatments have not been able to effectively alleviate the negative impact of NPC on patients' daily lives.

The FDA's approval is based on data provided by the international multi-center randomized double-blind placebo-controlled pivotal clinical trial IB1001-301 (registration number NCT05163288). The study evaluated the efficacy of leacetylleucine in children (4 years and older) and adults diagnosed with NPC, with a total of 60 participants. The trial results showed that patients treated with leacetylleucine experienced significant improvements in neurological symptoms and function, and these effects were particularly evident within 12 weeks. The primary efficacy endpoint and secondary endpoint were achieved in all treatment groups.

The study's primary assessment was a modified version of the Scale for Assessment and Rating of Ataxia (SARA), called functional SARA (fSARA). SARA is a clinical assessment tool that effectively evaluates a patient's gait, stability, speech and physical coordination. Functional SARA focuses on gait, sitting, standing, and speech impairments, and has an adjusted scoring system. Patients in the leacetylleucine group showed greater improvements in fSARA scores compared with placebo, with a mean treatment difference of -0.4 (95% CI: -0.7, -0.2) and a two-sided p-value of less than 0.001. This result is consistent with the results of the original SARA and further validates the efficacy of levoacetylleucine. In addition, levoacetylleucine was well tolerated in the trial and no serious adverse reactions occurred.

In summary, levoacetylleucine demonstrates its potential as a new therapy by improvingNPC patients’ neurological symptoms and daily functions, opening up a new direction for the treatment of this rare disease.

References:https://www.drugs.com/newdrugs/fda-approves-aqneursa-levacetylleucine-niemann-pick-type-c-6371.html